Visfatin May Be a Novel Marker for Identifying Stages of Essential Hypertension in Advanced Age Patients

Internal Medicine - Japan
doi 10.2169/internalmedicine.51.6609
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japanese Society of Internal Medicine

Related search

Serum Visfatin as a Novel Marker of Endothelial Dysfunction in Patients With Type 2 Diabetes

International Journal of Contemporary Medical Research [IJCMR]
2018English

Statins May Be Beneficial for Patients With Pulmonary Hypertension Secondary to Lung Diseases

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Microalbuminuria, an Integrated Marker of Cardiovascular Risk in Essential Hypertension

Journal of Human Hypertension
Internal Medicine
2002English

Routine Measurement of Fibrinogen Concentration. Fibrinogen May Be Just a Marker.

BMJ
1993English

Increased Mean Platelet Volume in Patients With Familial Mediterranean Fever May Not Be a Marker of Atherosclerosis Risk

Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology
2013English

Pretransplant Serum Ferritin Level May Be a Predictive Marker for Outcomes in Patients Having Undergone Allogeneic Hematopoietic Stem Cell Transplantation

Neoplasma
Cancer Research
2012English

Plasma Pentraxin 3 May Be a Better Marker of Peripheral Artery Disease in Hemodialysis Patients Than C-Reactive Protein

Vascular Medicine
MedicineCardiovascular MedicineCardiology
2013English

Serum TFF3 May Be a Pharamcodynamic Marker of Responses to Chemotherapy in Gastrointestinal Cancers

BMC Clinical Pathology
Forensic MedicinePathologyHistology
2014English

Ketanserin, a Novel 5-Hydroxytryptamine Antagonist: Monotherapy in Essential Hypertension.

British Journal of Clinical Pharmacology
Pharmacology
1983English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy